Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience

INTRODUCTION: Diabetic macular oedema (DMO) remains a significant cause of sight loss in the UK. Despite macular laser and anti-VEGF agents, a large proportion of patients remain with persistent DMO. We present our results of using 0.19 mg fluocinolone acetonide (FAc) intravitreal implant in this co...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, James F., Walkden, Andrew, Stone, Amy, Mahmood, Sajjad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692423/
https://www.ncbi.nlm.nih.gov/pubmed/31309417
http://dx.doi.org/10.1007/s40123-019-0197-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692423/
https://www.ncbi.nlm.nih.gov/pubmed/31309417
http://dx.doi.org/10.1007/s40123-019-0197-3

Ejemplares similares